secwatch.observer — SEC 8-K summary
======================================

Issuer:     MESA LABORATORIES INC /CO/ (MLAB)
CIK:        0000724004
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001437749-24-010537
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.06, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mesa Labs expects $271M non-cash impairment charge for FY2024, impacting two divisions
--------------------------------------------------------------------------------

- Non-cash impairment of ~$271M for Clinical Genomics and Biopharmaceutical Development divisions in Q4 FY2024.
- Goodwill impairment of ~$123M ($98M Clinical Genomics, $25M Biopharm Dev) and intangible asset impairment of ~$148M ($114M and $34M).
- Driven by restructuring (eliminated 17 positions), loss of Sema4 as customer, macro uncertainty, and higher discount rates.
- Non-cash charge does not affect cash flows from operations; final amounts subject to change upon 10-K filing.
- Management cites new strategies, downward revenue revisions, and elevated interest rates as key factors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/724004/000143774924010537/0001437749-24-010537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/724004/000143774924010537/mlab20240401_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-010537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer